Ultragenyx Pharma (RARE) Misses Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Ultragenyx Reports Third Quarter 2016 Financial Results and Corporate Update
November 7, 2016 4:05 PM ESTNOVATO, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended September 30, 2016.
Based on recent discussions with the FDA, we now plan to file for US approval of KRN23 in the second half of 2017, said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. We expect continued clinical and regulatory progress across all of our programs, including filings for rhGUS and... More
